Jounce Therapeutics, Inc. JNCE
Set alert
1.88 0.00 0.00%
At close · May 3
1.88 Day range 1.93
52-week range unavailable
- Open
- 1.92
- Prev close
- 1.88
- Mkt cap
- 98.95M
- Vol
- 11.60M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.88
- High
- 1.93
- Forward P/E
- -1.83
- Beta
- 0.75
- Short ratio
- 0.48
- Inst. own
- 85.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2023
- 50-d avg
- 1.64
- 200-d avg
- 1.93
- 1y target
- 2.00
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 6
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.68 | -0.68 – -0.68 | -0.72 | +5.6% | 0 | 0.0% | 1 |
| Next quarter | -0.09 | -0.09 – -0.09 | -0.65 | +86.2% | 0 | 0.0% | 1 |
| Current year | -0.96 | -0.96 – -0.96 | -0.99 | +3.0% | 5.00M | -93.9% | 1 |
| Next year | -1.03 | -1.03 – -1.03 | -0.96 | -7.3% | 5.00M | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 24, 2023 | SMBC Nikko | Downgrade | Outperform | Neutral |
| Feb 23, 2023 | Raymond James | Downgrade | Outperform | Market Perform |
| Jan 3, 2023 | Piper Sandler | Maintained | — | Overweight |
| Nov 11, 2022 | Raymond James | Downgrade | Strong Buy | Outperform |
| Aug 31, 2022 | Raymond James | Maintained | — | Strong Buy |
| Aug 5, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 23, 2022 | Piper Sandler | Maintained | — | Overweight |
| May 11, 2022 | Baird | Downgrade | Outperform | Neutral |
| May 6, 2022 | Raymond James | Upgrade | Outperform | Strong Buy |
| Mar 16, 2022 | SMBC Nikko | Initiated | — | Outperform |
| Feb 4, 2022 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Nov 5, 2021 | Raymond James | Maintained | — | Outperform |
| Sep 14, 2021 | Raymond James | Upgrade | Market Perform | Outperform |
| Mar 15, 2021 | Piper Sandler | Initiated | — | Overweight |
| Nov 10, 2020 | Roth Capital | Maintained | — | Buy |
| Nov 3, 2020 | Raymond James | Downgrade | Strong Buy | Market Perform |
| Sep 2, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| May 7, 2020 | H.C. Wainwright | Maintained | — | Buy |
| Mar 25, 2020 | Raymond James | Upgrade | Outperform | Strong Buy |
| Mar 2, 2020 | H.C. Wainwright | Reiterated | — | Buy |
| Nov 14, 2018 | JP Morgan | Downgrade | Neutral | Underweight |
| Oct 23, 2018 | Raymond James | Maintained | Outperform | Outperform |
| Aug 10, 2018 | JP Morgan | Maintained | Neutral | Neutral |
| Jun 28, 2018 | Raymond James | Initiated | — | Outperform |
| Jun 5, 2018 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jun 4, 2018 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 4, 2018 | Wells Fargo | Maintained | Market Perform | Market Perform |
| Jun 4, 2018 | Baird | Maintained | Outperform | Outperform |
| May 17, 2018 | Wells Fargo | Downgrade | Outperform | Market Perform |
| Apr 27, 2018 | H.C. Wainwright | Initiated | — | Buy |